Denali Therapeutics Inc
DNLI16.510USD
+0.100+0.61%
Close 12/31, 16:00（ET）Quotes delayed by 15 min
2.42BMarket Cap
LossP/E TTM
More Details of Denali Therapeutics Inc Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Denali Therapeutics Inc Info
Ticker SymbolDNLI
Company nameDenali Therapeutics Inc
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Number of employees422
Security typeOrdinary Share
Fiscal year-endDec 08
Address161 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508668547
Websitehttps://www.denalitherapeutics.com
Ticker SymbolDNLI
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Company Executives of Denali Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.46M
--
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
765.12K
-0.38%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
+1.74%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
+9.05%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
+28.08%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
+30.13%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 30
Updated: Sun, Nov 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.68%
Baillie Gifford & Co.
7.44%
BlackRock Institutional Trust Company, N.A.
6.50%
Biogen Inc
4.59%
T. Rowe Price Investment Management, Inc.
3.62%
Other
70.17%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.68%
Baillie Gifford & Co.
7.44%
BlackRock Institutional Trust Company, N.A.
6.50%
Biogen Inc
4.59%
T. Rowe Price Investment Management, Inc.
3.62%
Other
70.17%
Shareholder Types
Shareholders
Proportion
Investment Advisor
50.30%
Investment Advisor/Hedge Fund
18.27%
Hedge Fund
13.58%
Sovereign Wealth Fund
5.97%
Individual Investor
4.64%
Corporation
4.59%
Research Firm
2.24%
Bank and Trust
1.01%
Private Equity
0.64%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
523
144.23M
92.59%
-5.13M
2025Q3
534
148.30M
106.07%
+2.76M
2025Q2
533
144.90M
104.92%
+4.11M
2025Q1
521
140.91M
100.82%
-5.51M
2024Q4
508
135.26M
104.03%
-2.70M
2024Q3
500
139.34M
103.43%
+2.39M
2024Q2
486
129.82M
93.98%
+2.48M
2024Q1
475
127.09M
84.98%
+6.07M
2023Q4
485
116.85M
84.85%
+2.16M
2023Q3
479
114.98M
85.46%
+1.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
11.96M
7.68%
+173.41K
+1.47%
Sep 30, 2025
Baillie Gifford & Co.
11.59M
7.44%
-363.74K
-3.04%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.13M
6.5%
+257.90K
+2.61%
Sep 30, 2025
Biogen Inc
7.16M
4.59%
-5.60M
-43.89%
Oct 30, 2024
T. Rowe Price Investment Management, Inc.
5.64M
3.62%
+2.39M
+73.66%
Sep 30, 2025
State Street Investment Management (US)
5.46M
3.51%
+946.27K
+20.94%
Sep 30, 2025
Temasek Holdings Pte. Ltd.
5.36M
3.44%
--
--
Sep 30, 2025
Fidelity Management & Research Company LLC
5.01M
3.22%
-2.40M
-32.37%
Sep 30, 2025
Capital Research Global Investors
4.76M
3.06%
+10.28K
+0.22%
Sep 30, 2025
T. Rowe Price Associates, Inc.
4.43M
2.85%
-2.03M
-31.37%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.13%
Global X Guru Index ETF
1.33%
ALPS Medical Breakthroughs ETF
0.98%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
State Street SPDR S&P Biotech ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
Global X Aging Population ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.35%
iShares Health Innovation Active ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.23%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.13%
Global X Guru Index ETF
Proportion1.33%
ALPS Medical Breakthroughs ETF
Proportion0.98%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.74%
State Street SPDR S&P Biotech ETF
Proportion0.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.45%
Global X Aging Population ETF
Proportion0.38%
ProShares Ultra Nasdaq Biotechnology
Proportion0.35%
iShares Health Innovation Active ETF
Proportion0.35%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Denali Therapeutics Inc?
The top five shareholders of Denali Therapeutics Inc are:
The Vanguard Group, Inc. holds 11.96M shares, accounting for 7.68% of the total shares.
Baillie Gifford & Co. holds 11.59M shares, accounting for 7.44% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.13M shares, accounting for 6.50% of the total shares.
Biogen Inc holds 7.16M shares, accounting for 4.59% of the total shares.
T. Rowe Price Investment Management, Inc. holds 5.64M shares, accounting for 3.62% of the total shares.
The Vanguard Group, Inc. holds 11.96M shares, accounting for 7.68% of the total shares.
Baillie Gifford & Co. holds 11.59M shares, accounting for 7.44% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 10.13M shares, accounting for 6.50% of the total shares.
Biogen Inc holds 7.16M shares, accounting for 4.59% of the total shares.
T. Rowe Price Investment Management, Inc. holds 5.64M shares, accounting for 3.62% of the total shares.
What are the top three shareholder types of Denali Therapeutics Inc?
The top three shareholder types of Denali Therapeutics Inc are:
The Vanguard Group, Inc.
Baillie Gifford & Co.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Baillie Gifford & Co.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Denali Therapeutics Inc (DNLI)?
As of 2025Q4, 523 institutions hold shares of Denali Therapeutics Inc, with a combined market value of approximately 144.23M, accounting for 92.59% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -13.48%.
What is the biggest source of revenue for Denali Therapeutics Inc?
In --, the -- business generated the highest revenue for Denali Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
